WebAffiliations. 1 Sean M. Healey & AMG Center for ALS and Neurological Clinical Research Institute, Department of Neurology, Massachusetts General Hospital, Harvard Medical … WebHEALEY ALS Platform Trial PIs M. Cudkowicz & S. Paganoni Sean M. Healey & AMG Center for ALS •Statistical design and analysis support •Multiple regimens enter and exit …
Find A Researcher at Massachusetts General Hospital
WebFeb 28, 2024 · A new article describes the approach, structure, and launch of the HEALEY ALS Platform Trial- the first platform trial for amyotrophic lateral sclerosis (ALS) … WebMar 7, 2024 · The Phase 2/3 clinical trial testing UCB’s investigational therapy zilucoplan for amyotrophic lateral sclerosis (ALS) — one of the arms of the multi-regimen HEALEY ALS platform trial — has been stopped early based on interim data. The decision was made after a pre-specified analysis “demonstrated futility,” UCB said in a press release. baumer o500.sp manual
2024 American Academy of Neurology Abstract Website
WebDec 21, 2024 · Address correspondence to Dr Paganoni, Harvard Medical School, Sean M. Healey & AMG Center for ALS, Massachusetts General Hospital, 165 Cambridge St, … WebAffiliations. 1 Sean M. Healey & AMG Center for ALS and Neurological Clinical Research Institute, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA. 2 Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA. 3 Berry Consultants, Austin, TX. WebSep 27, 2024 · With this final regulatory authorization, Seelos may still meet its plans of starting patient dosing by the end of this month. SLS-005 will be evaluated in a pivotal Phase 2b/3 trial integrated into the HEALEY ALS Platform Trial (NCT04297683) — the first multi-regimen study in ALS, which already is testing four other potential treatments.The … tim robinson